Sudafed PE Dosage: 4 Label Charts and the FDA Order Still Pending

Quick Answer: The Sudafed PE Sinus Congestion label says adults and children 12 and over take 1 tablet (10 mg phenylephrine) every 4 hours and do not take more than 6 tablets in 24 hours; children under 12 should ask a doctor. Children’s Sudafed PE liquid (2.5 mg per 5 mL) is 5 mL for ages 4 to 5 and 10 mL for ages 6 to 11, every 4 hours, no more than 6 times in 24 hours, and is not for children under 4. The combination products use different charts, so the dose depends on the box, not the brand name. Separately, on 7 November 2024 the FDA proposed removing oral phenylephrine as a nasal decongestant because its review found it “is not effective for this use”. As of 14 October 2026 that is still a proposal: the FDA says products “can still be marketed until the agency issues a final order”, and we found no final order in the Federal Register. We do not link to any product on this page.

“Sudafed PE” is not one product. The PE line covers single-ingredient phenylephrine tablets, children’s liquid, and combinations with acetaminophen, ibuprofen, dextromethorphan or guaifenesin. Each has its own Drug Facts label, and the phenylephrine amount per tablet is not the same across them. This page copies the directions from the current labels on DailyMed, the National Library of Medicine’s label database, and then sets out what the FDA has said about whether oral phenylephrine works.

Sudafed PE dosage by product, from the labels

Every dose and limit below is quoted from the product’s Drug Facts label as published on DailyMed. We have not calculated any dose.

Two things follow from the table. First, a single “Sudafed PE” pill can hold 5 mg or 10 mg of phenylephrine, which is why the Pressure + Pain caplet is taken two at a time and the plain tablet one at a time. Second, the combination products bring their own limits for the second ingredient, and those can be the stricter limit. The Pressure + Pain caplet’s ceiling of 10 caplets is also a ceiling on acetaminophen; by our multiplication of the label figures, 10 caplets contain 3,250 mg of acetaminophen and 50 mg of phenylephrine.

The child’s liquid uses its own cup

The Children’s Sudafed PE label adds: “Attention: use only enclosed dosing cup specifically designed for use with this product. Do not use any other dosing device.” The chart is by age only; it gives no weight-based dose.

Who should check with a doctor first

The plain phenylephrine tablet’s label lists the same core warnings that appear across the PE line:

• Do not use “if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson’s disease), or for 2 weeks after stopping the MAOI drug.”
• Ask a doctor before use if you have “heart disease”, “high blood pressure”, “thyroid disease”, “diabetes” or “trouble urinating due to an enlarged prostate gland”.
• Stop use and ask a doctor if “nervousness, dizziness, or sleeplessness occur” or if “symptoms do not improve within 7 days or occur with a fever”.
• “If pregnant or breast-feeding, ask a health professional before use.”

The children’s liquid adds “a sodium-restricted diet” to its ask-a-doctor list. The acetaminophen combinations add the liver warning and “Do not use with any other drug containing acetaminophen (prescription or nonprescription)”. The ibuprofen combination adds the NSAID stomach-bleeding and heart-attack and stroke warnings. In case of overdose, every label gives the Poison Control number, 1-800-222-1222.

What the FDA has said about oral phenylephrine

This is the part most dosage pages leave out. On 7 November 2024 the FDA announced that it is “proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the temporary relief of nasal congestion after an agency review of the available data determined that oral phenylephrine is not effective for this use.”

The same announcement is careful about what this does and does not mean:

• “For now, companies may continue to market OTC monograph drug products containing oral phenylephrine as a nasal decongestant. This is a proposed order. Only a final order will affect what products can be marketed.”
• “The proposed order is based on effectiveness concerns, not on safety concerns.”
• “The FDA’s action is only related to orally administered phenylephrine and not the nasal spray form.”
• In combination products, “the presence of oral phenylephrine in these medicines does not affect how other active ingredients work to treat the symptoms for which they are intended.”

The proposal followed the FDA’s Nonprescription Drugs Advisory Committee meeting of 11 and 12 September 2023. In the FDA’s words, the committee “unanimously concluded that the current scientific data do not support that the recommended dosage in the OTC cold, cough, allergy, bronchodilator and antiasthmatic drug products monograph for orally administered phenylephrine’s effectiveness as a nasal decongestant.”

Where it stands today

The proposed order was published in the Federal Register on 8 November 2024 (document 2024-25910). It would remove “orally administered phenylephrine hydrochloride and phenylephrine bitartrate in an effervescent dosage as nasal decongestant active ingredients because they are not effective.” The comment period closed on 7 May 2025.

When we checked on 14 October 2026, the Federal Register’s list of FDA documents mentioning phenylephrine showed no final order after that proposal, and the FDA’s consumer page on oral phenylephrine (content current as of 7 November 2024) still says: “Drug products that contain oral phenylephrine can still be marketed until the agency issues a final order.” The FDA says that if it finalizes the decision it “would provide manufacturers with appropriate time to either reformulate drugs containing oral phenylephrine or remove such drugs from the market.”

So the label directions above are still the legal directions for products on the shelf. What has changed is the FDA’s stated view of whether the decongestant ingredient in them works.

Is it safe?

The FDA’s position is that the issue is effectiveness. Its consumer page says: “Even though oral phenylephrine is widely used, FDA identified very few cases of serious side effects when oral phenylephrine is taken by consumers as directed in the label of the drug product.” It also says that if you have a product containing it, “you may continue to use it.”

What the trials found

The FDA’s conclusion rests on studies that are public. Four of the main ones, read from their abstracts:

• Hatton 2007, systematic review and meta-analysis. In 8 unpublished studies with 138 patients, phenylephrine 10 mg “did not affect NAR [nasal airway resistance] more than placebo”. The authors concluded: “There is insufficient evidence that oral phenylephrine is effective for nonprescription use as a decongestant.”
• Horak 2009, allergen challenge chamber. 39 people with grass allergy received phenylephrine 12 mg, pseudoephedrine 60 mg or placebo. Phenylephrine “was not significantly different from placebo” on the main congestion score (P = .56), “whereas pseudoephedrine was significantly more effective than both placebo (P < .01) and phenylephrine (P = .01).”
• Meltzer 2015, dose-ranging trial. 539 adults with seasonal allergies took 10, 20, 30 or 40 mg or placebo for 7 days. “None of the PE HCl treatment groups had a statistically significant change from baseline” in congestion scores compared with placebo. Conclusion: phenylephrine “at doses of up to 40 mg every 4 hours, is not significantly better than placebo”. The trial was open-label, and one author was employed by Merck.
• Meltzer 2016, modified-release tablets. 575 patients took 30 mg modified-release phenylephrine or placebo every 12 hours for 7 days. “No significant beneficial difference was detected between PEH-MR and placebo for the primary end point” (P = .2655).

The Meltzer 2015 result matters for the dosage question in particular: taking more than the label dose did not make it work. Up to four times the labelled 10 mg dose was not better than placebo, while the label’s own limit exists because of the side-effect warnings.

Sudafed PE vs Sudafed: two different drugs

The plain “Sudafed” products contain pseudoephedrine, not phenylephrine. The Sudafed Sinus Congestion label lists “Pseudoephedrine HCl 30 mg” per tablet, with directions for adults and children 12 and over to “take 2 tablets every 4 to 6 hours” and “do not take more than 8 tablets in 24 hours”; children 6 to 11 take 1 tablet every 4 to 6 hours, no more than 4 in 24 hours; and “do not use this product in children under 6 years of age”.

Pseudoephedrine is sold differently. According to the FDA, “The sale of cold medicine containing pseudoephedrine is limited to behind the counter. The amount of pseudoephedrine that an individual can purchase each month is limited and individuals are required to present photo identification to purchase products containing pseudoephedrine.” Sellers must also keep a “logbook” of sales.

The FDA’s consumer page lists pseudoephedrine among the alternatives for nasal congestion: “Other OTC drugs that can be used to treat nasal congestion include oral pseudoephedrine and nasal sprays with nasal decongestants, nasal corticosteroids and nasal antihistamines.” For children it also mentions “cool mist humidifiers, saline nose drops or sprays, and nasal suctioning with a bulb syringe.” Pseudoephedrine carries its own warnings, including the same MAOI and heart, blood pressure, thyroid, diabetes and prostate cautions on its label, so it is a question for a pharmacist rather than a straight swap.

How to read your own box

1. Find the phenylephrine line in the Active ingredients box and note the mg per tablet, caplet or 5 mL.
2. Use that label’s chart, not another Sudafed PE product’s. The plain tablet is 1 every 4 hours; the Pressure + Pain caplet is 2 every 4 hours.
3. Check the other active ingredients. If the box contains acetaminophen or ibuprofen, do not take another product with the same ingredient.
4. Respect the 7-day stop rule on the label, and stop sooner if you become nervous, dizzy or sleepless.
5. For a child, check the age line first. The children’s liquid starts at 4 years; the adult tablets say to ask a doctor under 12.

Several Sudafed PE combination boxes also contain dextromethorphan, the cough suppressant in Delsym and Robitussin DM. Its labels have their own dosing clocks and an MAOI warning; we set them out in our dextromethorphan dosage page.

Frequently Asked Questions

How much Sudafed PE can I take in a day?

For Sudafed PE Sinus Congestion tablets (10 mg phenylephrine), the label says adults and children 12 and over take 1 tablet every 4 hours and “do not take more than 6 tablets in 24 hours.” Combination products have different charts, so read the label on your box.

How often can you take Sudafed PE?

The single-ingredient tablet and the children’s liquid are labelled every 4 hours. The Pressure + Pain caplet is 2 caplets every 4 hours, with no more than 10 caplets in 24 hours.

What is the Sudafed PE dose for children?

Children’s Sudafed PE Nasal Decongestant liquid (2.5 mg per 5 mL) is 5 mL for ages 4 to 5 and 10 mL for ages 6 to 11, repeated every 4 hours, no more than 6 times in 24 hours. The label says “do not use” under 4 years. The adult tablets say children under 12 should ask a doctor.

Does Sudafed PE actually work?

The FDA proposed in November 2024 to remove oral phenylephrine as a nasal decongestant after its review “determined that oral phenylephrine is not effective for this use.” Its 2023 advisory committee was unanimous, and trials up to 40 mg every 4 hours found no benefit over placebo. The FDA says the concern is effectiveness, not safety.

Is Sudafed PE being banned?

Not yet. As of 14 October 2026 the FDA’s action is a proposed order. The FDA says products “can still be marketed until the agency issues a final order,” and we found no final order in the Federal Register. Nasal sprays containing phenylephrine are not part of the proposal.

What is the difference between Sudafed and Sudafed PE?

Sudafed contains pseudoephedrine (30 mg per tablet on the Sinus Congestion label) and is sold behind the pharmacy counter with ID and monthly purchase limits. Sudafed PE contains phenylephrine and is sold on the open shelf.

The Bottom Line

The dose on a Sudafed PE box is whatever that box’s label says, and the line varies: 10 mg tablets taken one at a time every 4 hours up to 6 a day, 5 mg combination caplets taken two at a time up to 10 a day, and a children’s liquid by age from 4 years. What the label does not tell you is that the FDA has proposed removing oral phenylephrine as a decongestant because it does not work, a proposal still pending as of mid-October 2026. If your congestion is the reason you are reaching for it, the FDA’s own page points to other options and suggests asking a pharmacist.

Sources

1. DailyMed. SUDAFED PE Sinus Congestion (phenylephrine hydrochloride) tablet, Kenvue Brands LLC, set ID 2ca08917-1a75-4365-8520-c083e6a4225a (published 11 Nov 2024). Phenylephrine HCl 10 mg; “take 1 tablet every 4 hours”; “do not take more than 6 tablets in 24 hours”; “children under 12 years ask a doctor”; MAOI, ask-a-doctor and stop-use warnings. dailymed.nlm.nih.gov. Checked 14 October 2026.
2. DailyMed. Children’s SUDAFED PE Nasal Decongestant (phenylephrine hydrochloride) solution, set ID 4dfd46e4-b9f9-464d-aa47-e8fa9e526a5d (published 15 Nov 2024). 2.5 mg per 5 mL; under 4 years do not use; 4 to 5 years 5 mL; 6 to 11 years 10 mL; every 4 hours; not more than 6 times in 24 hours; enclosed dosing cup. dailymed.nlm.nih.gov. Checked 14 October 2026.
3. DailyMed. SUDAFED PE Pressure Plus Pain (acetaminophen and phenylephrine hydrochloride) caplet, set ID 8538c291-9ce9-4866-b268-f4cbdb52f5bd (published 11 Nov 2024); and Sudafed PE Sinus Pressure Plus Pain tablet, set ID 67428f4b-28be-4682-a9a9-781bf85089ff (published 12 Mar 2026). Acetaminophen 325 mg and phenylephrine HCl 5 mg per unit; 2 every 4 hours; not more than 10 in 24 hours. dailymed.nlm.nih.gov. Checked 14 October 2026.
4. DailyMed. SUDAFED PE Head Congestion Plus Pain (ibuprofen and phenylephrine hydrochloride) caplet, set ID 76513fb2-7323-4f1f-8a10-92f8f603cf97 (published 13 Mar 2025). Ibuprofen 200 mg and phenylephrine HCl 10 mg; 1 caplet every 4 hours; not more than 6 caplets in any 24-hour period; under 12 do not use. dailymed.nlm.nih.gov. Checked 14 October 2026.
5. DailyMed. SUDAFED Sinus Congestion (pseudoephedrine hydrochloride) tablet, set ID c05d7e27-6821-468f-b27d-9c0b02a07b0f (published 11 Nov 2024). Pseudoephedrine HCl 30 mg; adults 2 tablets every 4 to 6 hours, not more than 8 in 24 hours; children 6 to 11 years 1 tablet, not more than 4 in 24 hours; under 6 do not use. dailymed.nlm.nih.gov. Checked 14 October 2026.
6. U.S. Food and Drug Administration. FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review. Press announcement, 7 November 2024. Quotes on the proposal, “Only a final order will affect what products can be marketed”, “effectiveness concerns, not on safety concerns”, nasal spray exclusion, and the advisory committee’s unanimous conclusion. fda.gov. Checked 14 October 2026.
7. U.S. Food and Drug Administration. Key Information about Nonprescription, Over-the-Counter (OTC), Oral Phenylephrine. Content current as of 11/07/2024. “can still be marketed until the agency issues a final order”; “very few cases of serious side effects”; alternatives including oral pseudoephedrine and nasal sprays; humidifiers and saline for children. fda.gov. Checked 14 October 2026.
8. Federal Register. Amending Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use. Document 2024-25910, 8 November 2024; proposed order OTC000036; comments by 7 May 2025. Federal Register search for FDA documents mentioning phenylephrine on 14 October 2026 showed no later final order. federalregister.gov. Checked 14 October 2026.
9. U.S. Food and Drug Administration. Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine, Ephedrine, and Phenylpropanolamine. Content current as of 07/12/2024. Behind-the-counter sale, monthly purchase limit, photo identification, sales logbook. fda.gov. Checked 14 October 2026.
10. Hatton RC, Winterstein AG, McKelvey RP, Shuster J, Hendeles L. Efficacy and safety of oral phenylephrine: systematic review and meta-analysis. Ann Pharmacother. 2007;41(3):381-390. 8 unpublished studies, 138 patients; 10 mg did not affect nasal airway resistance more than placebo; “insufficient evidence”. PMID 17264159. Checked 14 October 2026.
11. Horak F, Zieglmayer P, Zieglmayer R, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. Ann Allergy Asthma Immunol. 2009;102(2):116-120. 39 patients; phenylephrine 12 mg vs placebo P = .56; pseudoephedrine 60 mg better than placebo (P < .01) and phenylephrine (P = .01). PMID 19230461. Checked 14 October 2026.
12. Meltzer EO, Ratner PH, McGraw T. Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study. J Allergy Clin Immunol Pract. 2015;3(5):702-708. 539 adults; 10, 20, 30 or 40 mg for 7 days; not significantly better than placebo; author affiliation Merck & Co. PMID 26143019. Checked 14 October 2026.
13. Meltzer EO, Ratner PH, McGraw T. Phenylephrine hydrochloride modified-release tablets for nasal congestion: a randomized, placebo-controlled trial in allergic rhinitis patients. Ann Allergy Asthma Immunol. 2016;116(1):66-71. 575 patients; 30 mg modified-release every 12 hours for 7 days; P = .2655 vs placebo. PMID 26560899. Checked 14 October 2026.